Agile Therapeutics Inc. (NASDAQ:AGRX)’s share price fell 5.2% during mid-day trading on Wednesday . The stock traded as low as $6.99 and last traded at $7.09, with a volume of 63,974 shares changing hands. The stock had previously closed at $7.48.

Several research firms recently issued reports on AGRX. FBR & Co reissued a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, June 2nd. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Tuesday, May 31st. Finally, Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $15.17.

The stock’s market cap is $213.84 million. The stock has a 50 day moving average of $7.54 and a 200-day moving average of $6.79.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.11. On average, equities research analysts predict that Agile Therapeutics Inc. will post ($1.12) earnings per share for the current year.

An institutional investor recently raised its position in Agile Therapeutics stock. EAM Investors LLC boosted its stake in Agile Therapeutics Inc. (NASDAQ:AGRX) by 0.4% during the fourth quarter, Holdings Channel reports. The firm owned 137,018 shares of the specialty pharmaceutical company’s stock after buying an additional 540 shares during the period. EAM Investors LLC owned approximately 0.61% of Agile Therapeutics worth $1,337,000 at the end of the most recent quarter.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.